Pulmonary hypertension in connective tissue diseases: an update

Area of Science:

• Rheumatology
• Cardiology
• Pulmonology

Background:

• Pulmonary hypertension (PH) is a frequent complication of systemic sclerosis (SSc), affecting 8-12% of patients and contributing significantly to morbidity and mortality.
• Connective tissue disease-associated PH (CTD-PAH) falls under group 1 PH, specifically pulmonary arterial hypertension (PAH), and accounts for a substantial portion of deaths in scleroderma patients.
• The pathogenesis involves pulmonary vasculopathy affecting small vessels, highlighting the need for effective screening and management strategies.

Purpose of the Study:

• To evaluate the efficacy of the Evidence-based Detection of Pulmonary Arterial Hypertension in Systemic sclerosis (DETECT) algorithm as a screening tool for SSc-PAH.
• To discuss the role of specific therapies, including anticoagulation and immunosuppression, in managing CTD-PAH.
• To compare treatment outcomes in CTD-PAH patients with those of idiopathic PAH.

Main Methods:

• Comparison of the DETECT algorithm against current European Society of Cardiology/European Respiratory Society guidelines for SSc-PAH screening.
• Analysis of data from major clinical trials involving CTD-PAH patients.
• Review of the risk-benefit profiles of anticoagulation and immunosuppressive therapies in CTD-PAH.

Main Results:

• The DETECT algorithm demonstrates superior performance compared to existing guidelines for identifying SSc-PAH, aiding in timely referral for right heart catheterization.
• CTD-PAH patients represent at least 20% of participants in major PH therapy trials, with comparable treatment responses to idiopathic PAH.
• Anticoagulation in CTD-PAH carries a high risk-benefit ratio, potentially beneficial in severe cases. Immunosuppression is generally not indicated for scleroderma-PAH, but may benefit subsets of patients with other CTDs like lupus.

Conclusions:

• The DETECT algorithm is a valuable tool for screening SSc-PAH, improving diagnostic pathways.
• Treatment responses in CTD-PAH are similar to idiopathic PAH, suggesting shared underlying mechanisms.
• Therapeutic strategies for CTD-PAH should be individualized, with caution regarding anticoagulation and limited role for immunosuppression in scleroderma-PAH.